Skip to main content

Advertisement

Table 1 Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups

From: Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

Okuda category I-II III or unknown
  Tamoxifen (n = 189) Control (n = 196) Tamoxifen (n = 48) Control (n = 44)
Median (range) age, years 66 (39–91) 67 (42–84) 62 (37–86) 66 (31–80)
Men 133 (70.4) 144 (73.5) 36 (75.0) 39 (88.6)
Evidence of disease at entry 178 (94.2) 184 (93.9) 40 (83.3) 39 (88.6)
Interval between diagnosis and entry     
   0–6 months 150 (79.4) 161 (82.1) 44 (91.7) 38 (86.7)
   7–12 months 20 (10.6) 15 (7.7) 1 (2.1) 4 (9.1)
   13–24 months 19 (10.1) 20 (10.2) 6 (6.3) 2 (4.6)
Child-Pugh category     
   A 90 (47.6) 98 (50.0) 25 (52.1) 20 (45.6)
   B 82 (43.4) 75 (38.3) 13 (27.1) 11 (25.0)
   C 17 (9.0) 23 (11.7) 9 (18.8) 12 (27.3)
   unknown 0 (0.0) 0 (0.0) 1 (2.1) 1 (2.3)
Locoregional treatment     
   Surgery 11 (5.8) 12 (6.1) 7 (14.6) 3 (6.8)
   Percutaneous Ethanol Injection 61 (32.3) 72 (36.7) 3 (6.3) 6 (13.6)
   Transarterial chemoembolization 31 (16.4) 33 (16.8) 11 (22.9) 5 (11.4)
   none 86 (45.5) 79 (40.3) 27 (56.3) 30 (68.2)